Vascular Biogenics: The IPO That Wasn’t
It was the IPO that wasn’t: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn’t issuing shares after all, thanks to a key investor’s failure to follow through on a commitment to buy stock. Dan Strumpf joins MoneyBeat with Paul Vigna.
“Vascular Biogenics: The IPO That Wasn’t” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.